Stephen Maebius and Jennie Zheng Contribute to Article on Next-Gen Bioprinted Products
14 March 2023
Foley & Lardner LLP Partner Stephen Maebius and Patent Agent Jennie Zheng contributed to an article in IEEE Pulse titled, “ Next Generation Bioprinted Products: Products of Nature or Patentable Innovation ” in Volume 14, Issue 1 of the publication.
The authors describe the process of bioprinting, and its present use cases to generate a diverse range of products like ear and bone and its future potential across further complex matters, including a wide range of human organs. They then discuss the many aspects of bioprinting that are patent eligible, and examine potential strategies that may allow U.S. patents to be granted even on the end products.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”